Liquid chromatography–tandem mass spectrometry-based proteomics for peptide mapping
and sequencing was used to characterize the marketed monoclonal antibody trastuzumab …

This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth
characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar …

The approval process for antibody biosimilars relies primarily on comprehensive analytical
data to establish comparability and high similarity with the originator. Mass spectrometry …

As research, development, and manufacturing of biosimilar protein therapeutics proliferates,
there is great interest in the continued development of a portfolio of complementary …

This study shows that state-of-the-art liquid chromatography (LC) and mass spectrometry
(MS) can be used for rapid verification of identity and characterization of sequence variants …

Liquid chromatography mass spectrometry (LC–MS) is the most commonly used technique
for the characterization of antibody variants. MAb-X and mAb-Y are two approved IgG1 …

Mass spectrometry (MS) is one of the key analytical techniques to detect and to identify
primary sequence differences, to assess similarity and to evaluate batch variability of …

Out of all categories, monoclonal antibody (mAb) therapeutics attract the most interest due to
their strong therapeutic potency and specificity. Six of the 10 top-selling drugs are antibody …

In the last decade, the advancement of liquid chromatography mass spectrometry (LC/MS)
techniques has enabled their broad application in protein characterization, both …

Comprehensive characterization of therapeutic monoclonal antibody (mAb) structures is
critical for drug development but remains challenging due to the inherent structural …